

Pro Anima Scientific Committee

A national and transdisciplinary hub for NAMs

Lilas Courtot, PhD, Responsable scientifique, Comité scientifique Pro Anima - contact: lilas@proanima.fr

Pro Anima (from the Latin for *breath, life*), was created in 1989 by Christiane Laupie-Koechlin under the honorary presidency of Professor Théodore Monod

Developing NAMs based on human data means [1]:

01

Increasing the understanding of human pathologies

02

Improving the risk assessment of chemicals

03

Reducing time and costs of preclinical studies

Communication activities

- Joining congress and events
- Oral presentations
- NAMs training
- Scientific publications [2,3]
- Social media post
- Quarterly NAMs magazine (experts articles and ITW)

Enhance and accelerate NAMs

approaches and technologies centered on human data (complex 3D *in vitro* models, AI, digital twins...)

Raise awareness and inform

Scientists, policymakers, civil society on NAMs' potential for health, competitiveness and sovereignty

4

MAIN MISSIONS

Support, enhance and facilitate dialogue

key players (industry, public research, and regulatory agencies) at the French and European levels

Fund and award research

with the Descroix-Vernier EthicScience Prize, exclusively dedicated to non-animal methods

NAMs network & Live Talks

Linkedin private group



NAMs Live Talks

> 480

Cross sector

- Academia
- Biotech
- Industry
- Institution
- NGO

> 35 countries


A Biennial NAMs Prize
€110,000 - 3 categories

PRIX DESCROIX-VERNIER
ETHICSOURCE
LA SCIENCE A UNE ÂME

Since in 2013

entirely dedicated to cutting-edge models and technologies that could yield more conclusive results than traditional models

NAMs Interface



Resources, Structures / Providers, Animal-Free Biomaterials, Events, Calls


Activities and Resources

Identify and overcome barriers to NAMs

- Clear and harmonised definition of NAMs [4]
- Education and training needs [5]
- Validation needs
- Socio-technical barriers [6]
- Lack of funds
- *In vivo* bias in publishing and fundings [7]

Weekly newsletter on NAMs

- By email
- On our website
- On social media



Team and Scientific Board



Christiane Laupie-Koechlin
Founder and General Secretary



Emeline Gougeon
Head of Strategy / Development



Dr Nicolas AZNAR



Dr Carole CHARMEAU



Dr Kevin GILLOIS



Dr Jean-Dominique GUITTON



Love HANSELL



Dr Sophie LELIEVRE



Dr Benoît MAISONNEUVE



Dr Julien NARBONNE



Dr Lilas Courtot
Scientific Manager



Dr Jean-Pierre Cravedi
President of the Scientific Board



Dr Nathalie PRINTEMPS



Dr Michel ROCHETTE



Dr Paul THOMAS



Dr Marc VEILLY

Network & Partners



PARC



Corporate members



References

- [1] 'NAMs: a paradigm change in biomedical research and toxicology' - Pro Anima Scientific Board (2026) [Online].
- [2] L. Courtot et al., NAM Journal (2025), doi: [10.1016/j.namjnl.2025.100027](https://doi.org/10.1016/j.namjnl.2025.100027).
- [3] R. Cash and L. Courtot, ALTEX, (2025), doi: [10.14573/altex.2501292](https://doi.org/10.14573/altex.2501292).
- [4] A. Ahluwalia et al., Lab Anim (2026), doi: [10.1038/s41684-026-01731-8](https://doi.org/10.1038/s41684-026-01731-8).
- [5] M. R. E. Janssens et al., ALTEX (2025) doi: [10.14573/altex.2411251](https://doi.org/10.14573/altex.2411251).
- [6] Aurelia, 'Report on Socio-Technical Barriers to the Uptake of NAMs' - PrecisionTox (2024) [Online].
- [7] C. E. Krebs et al., NAM Journal (2025), doi: [10.1016/j.namjnl.2024.100004](https://doi.org/10.1016/j.namjnl.2024.100004).

@ComiteProAnima



COMITÉ SCIENTIFIQUE
PRO ANIMA